Schultz KA, Ness KK, Nagarajan R, Steiner ME. Adnexal masses in infancy and Childhood. Clin Obstet Gynecol. 2006;49:464–79.

Article  PubMed  Google Scholar 

Marcus CS, Maxwell GL, Darcy KM, Hamilton CA, McGuire WP. Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. J Cancer. 2014;5:25–30.

Article  PubMed  PubMed Central  Google Scholar 

Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol EJSO. 2007;33:266–70.

Article  CAS  PubMed  Google Scholar 

Cure MC, Cure E, Kirbas A, Yazici T, Yuce S. Requests for tumor marker tests in Turkey without indications and frequency of elevation in benign conditions. Asian Pac J Cancer Prev. 2012;13:6485–9.

Article  PubMed  Google Scholar 

Susan Troup. Carbohydrate antigen 19‐9 (CA 19‐9) Analyte Monographs alongside the National Laboratory Medicine Catalogue. The Association for Clinical Biochemistry and Laboratory Medicine; 2012. http://www.acb.org.uk/Nat%20Lab%20Med%20Hbk/CA19-9.pdf

Park H-D, Park KU, Song J, Ki C-S, Han KS, Kim JQ. The relationship between Lewis/Secretor genotypes and serum carbohydrate antigen 19-9 levels in a Korean population. Korean J Lab Med. 2010;30:51–7.

CAS  PubMed  Google Scholar 

Wiest I, Schulze S, Kuhn C, Seliger C, Hausmann R, Betz P, et al. Expression of the carbohydrate tumour marker SLeX, SLeA (CA19-9), LeY and Thomsen-Friedenreich (TF) antigen on normal squamous epithelial tissue of the penis and vagina. Anticancer Res. 2007;27:1981–8.

CAS  PubMed  Google Scholar 

Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology. 2006;70:255–64.

Article  CAS  PubMed  Google Scholar 

Madaan M, Puri M, Sharma R, Kaur H, Trivedi SS. Unusually high levels of CA19-9 associated with mature cystic teratoma of the ovary. Case Rep Obstet Gynecol. 2014. https://doi.org/10.1155/2014/187910.

Article  PubMed  PubMed Central  Google Scholar 

Dede M, Gungor S, Yenen MC, Alanbay I, Duru NK, Haşimi A. CA19-9 may have clinical significance in mature cystic teratomas of the ovary. Int J Gynecol Cancer. 2006;16:189–93.

Article  CAS  PubMed  Google Scholar 

Suh DS, Moon SH, Kim SC, Joo JK, Park WY, Kim KH. Significant simultaneous changes in serum CA19-9 and CA125 due to prolonged torsion of mature cystic teratoma of the ovary. World J Surg Oncol. 2014;12:353.

Article  PubMed  PubMed Central  Google Scholar 

Artunc Ulkumen B, Goker A, Pala HG, Ordu S. Abnormal elevated CA 19-9 in the dermoid cyst: a sign of the ovarian torsion? Case Rep Obstet Gynecol. 2013;2013: 860505.

PubMed  PubMed Central  Google Scholar 

Ayhan A, Guven S, Guven ESG, Kucukali T. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Acta Obstet Gynecol Scand. 2007;86:484–90.

Article  CAS  PubMed  Google Scholar 

Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother. 2004;58:24–38.

Article  CAS  PubMed  Google Scholar 

Kelly PJ, Archbold P, Price JH, Cardwell C, McCluggage WG. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol. 2010;63:169–73.

Article  CAS  PubMed  Google Scholar 

Babacan A, Kizilaslan C, Gun I, Muhcu M, Mungen E, Atay V. CA 125 and other tumor markers in uterine leiomyomas and their association with lesion characteristics. Int J Clin Exp Med. 2014;7:1078–83.

CAS  PubMed  PubMed Central  Google Scholar 

Pyeon S-Y, Park JY, Ki K-D, Lee J-M. Abnormally high level of CA-19-9 in a benign ovarian cyst. Obstet Gynecol Sci. 2015;58:530–2.

Article  PubMed  PubMed Central  Google Scholar 

Ueda Y, Enomoto T, Kimura T, Miyatake T, Yoshino K, Fujita M, et al. Serum biomarkers for early detection of gynecologic cancers. Cancer. 2010;2:1312–27.

Article  CAS  Google Scholar 

Howaizi M, Abboura M, Krespine C, Sbai-Idrissi M-S, Marty O, Djabbari-Sobhani M. A new cause for CA19.9 elevation: heavy tea consumption. Gut. 2003;52:913–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawai S, Suzuki K, Nishio K, Ishida Y, Okada R, Goto Y, et al. Smoking and serum CA19-9 levels according to Lewis and secretor genotypes. Int J Cancer. 2008;123:2880–4.

Article  CAS  PubMed  Google Scholar 

Cho DH, Lee JH, Oh BC. Unusual presentation of retroperitoneal leiomyosarcoma mimicking an adnexal tumor with highly elevated serum CA-19-9. Obstet Gynecol Sci. 2014;57:77–81.

Article  PubMed  PubMed Central  Google Scholar 

Amonkar SD, Bertenshaw GP, Chen T-H, Bergstrom KJ, Zhao J, Seshaiah P, et al. Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS ONE. 2009;4(2): e4599.

Article  PubMed  PubMed Central  Google Scholar 

Nolen BM, Lokshin AE. The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid. Int J Biol Markers. 2011;26:141–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peng D, Xu T, Mason TJ, Wu W. A study of ovarian cancer biomarker amplification using ultrasound for early stage detection. Ultrasonics. 2014;54:451–4.

Article  CAS  PubMed  Google Scholar 

Nakagawa N, Koda H, Nitta N, Nakahara Y, Uno J, Hashimoto T, et al. Reactivity of CA19-9 and CA125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis. Acta Med Okayama. 2015;69:227–35.

CAS  PubMed  Google Scholar